AB Science S.A. ABSCF
1.12 USD 0.00 (+0.00%)
At closeNov 9, 2026, 4:00 PM EST
2.70 Day range 2.70
1.12 52-week range 2.70
- YTD
- -22.76%
- 1 year
- -11.11%
News
globenewswire.com AB Science is invited to present at the 2026 ENCALS annual meeting the survival data from masitinib clinical program in ALS PRESS RELEASE AB SCIENCE IS INVITED TO PRESENT AT THE 2026 ENCALS ANNUAL MEETING THE SURVIVAL DATA FROM MASITINIB CLINICAL PROGRAM IN AMYOTROPHIC LATERAL SCLEROSIS Masitinib treatment has been linked…
globenewswire.com AB Science : Stonegate Capital Partners updates its coverage of AB Science's stock with a target price of EUR 4.25 per share PRESS RELEASE STONEGATE CAPITAL PARTNERS UPDATES ITS COVERAGE OF AB SCIENCE'S STOCK WITH A DISCOUNTED CASH FLOW VALUATION MID-POINT OF EUR 4.25 PER SHARE Paris, June 2 nd , 2026, 6pm CET AB Science…
globenewswire.com AB Science announces that its stock continues to be covered by Maxim Group, with a target price of €4.00 per share PRESS RELEASE FOLLOWING RELEASE OF FYE2025 RESULTS AND SECURING OF CLINICAL TRIAL INSURANCE POLICY, MAXIM GROUP REITERATES ITS BUY RECOMMENDATION ON AB SCIENCE'S STOCK WITH A TARGET PRICE OF EUR 4.0…
globenewswire.com AB Science reports its revenues for the year 2025 and provides an update on its activities PRESS RELEASE AB SCIENCE PRESENTS ITS ANNUAL FINANCIAL RESULTS AS OF 31 DECEMBER 2025 AND KEY EVENTS FOR THE PERIOD Financial and corporate position Operating loss of €3.8 million as of 31 December…
globenewswire.com AB Science announces the successful completion of a EUR 3.2 million private placement PRESS RELEASE AB SCIENCE ANNOUNCES THE SUCCESSFUL COMPLETION OF A EUR 3.2 MILLION PRIVATE PLACEMENT Paris, April 29, 2026, 8am AB Science S.A. (the “Company” or “AB Science”, Euronext – FR0010557264…
globenewswire.com AB Science announces a final agreement on the renegotiation of the repayment terms of its loans with all of its financial creditors PRESS RELEASE AB SCIENCE announces a final agreement on the renegotiation of the repayment terms of its loans with all of its financial creditors AB Science has reached a final agreement with its…
globenewswire.com AB Science: New publication on medrxiv demonstrating substantial survival benefits and preserved quality of life with masitinib in ALS patients PRESS RELEASE AB SCIENCE ANNOUNCES NEW PUBLICATION ON MEDRXIV DEMONSTRATING SUBSTANTIAL SURVIVAL BENEFITS AND PRESERVED QUALITY OF LIFE WITH MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS PATIENTS…
globenewswire.com AB Science provides an update on its clinical development program. PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON ITS CLINICAL PROGRAM AB SCIENCE SECURES EUR 25 MILLION CLINICAL TRIAL INSURANCE FOR ITS PHASE III TRIAL IN AMYOTROPHIC LATERAL SCLEROSIS THE POLICY…
globenewswire.com AB Science announces the identification of a plasma biomarker that indicates the activity of masitinib in treating ALS PRESS RELEASE AB SCIENCE ANNOUNCES THE IDENTIFICATION OF A PLASMA BIOMARKER THAT INDICATES THE ACTIVITY OF MASITINIB IN TREATING AMYOTROPHIC LATERAL SCLEROSIS, AND THAT IS CAPABLE OF IDENTIFYING…
newsfilecorp.com Stonegate Capital Partners Initiates Coverage on AB Science S.A. (AB) Dallas, Texas--(Newsfile Corp. - February 10, 2026) - AB Science S.A. (ENXTPA: AB): Stonegate Capital Partners Initiates Coverage on AB Science S.A.
globenewswire.com AB Science announced that the Food and Drug Administration (FDA) granted the status of Minor Use in Major Species (MUMS) for Masivet® in the treatment of canine mast cell tumors PRESS RELEASE AB SCIENCE ANNOUNCES THAT THE FDA HAS GRANTED THE STATUS OF MINOR USE IN MAJOR SPECIES DESIGNATION FOR MASIVET IN THE TREATMENT OF CANINE MAST CELL TUMORS AB SCIENCE PRESENTS…
globenewswire.com AB Science receives Japanese patent protection for the use of masitinib in progressive forms of multiple sclerosis (MS) until 2041 PRESS RELEASE AB SCIENCE RECEIVES JAPANESE PATENT PROTECTION FOR THE USE OF MASITINIB IN PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS (MS) UNTIL 2041 THIS IS THE FIRST COUNTRY DELIVERING THE MS PATENT…
globenewswire.com AB Science reports fourth consecutive case of response from Phase 1 data for the combination of AB8939 with venetoclax for the treatment of refractory or relapsed acute myeloid leukemia PRESS RELEASE AB SCIENCE REPORTS FOURTH CONSECUTIVE CASE OF RESPONSE FROM PHASE 1 DATA FOR THE COMBINATION OF AB8939 WITH VENETOCLAX FOR THE TREATMENT OF REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA…
globenewswire.com AB Science patent for masitinib in the treatment of sickle cell disease formally granted in the US with a protection until 2040 PRESS RELEASE AB SCIENCE PATENT FOR MASITINIB IN THE TREATMENT OF SICKLE CELL DISEASE FORMALLY GRANTED IN THE UNITED STATES WITH A PROTECTION UNTIL 2040 THIS DECISION STRENGTHENS MASITINIB'S…
globenewswire.com AB Science announces the initiation of coverage of its stock by Maxim Group with a target price of EUR 4.0 per share PRESS RELEASE AB SCIENCE ANNOUNCES THE INITIATION OF COVERAGE OF ITS STOCK BY MAXIM GROUP WITH A TARGET PRICE OF EUR 4.0 PER SHARE Paris, December 18, 2025, 7.15pm CET AB Science SA (Euronext -…
globenewswire.com AB Science announces a new publication on biorxiv that identifies AB8939 as a promising drug candidate for treating refractory acute myeloid leukemia and potentially other cancers PRESS RELEASE AB SCIENCE ANNOUNCES A NEW PUBLICATION ON BIORXIV THAT IDENTIFIES AND CHARACTERIZES A NOVEL SMALL SYNTHETIC MOLECULE, AB8939, AS A PROMISING DRUG CANDIDATE FOR TREATING REFRACTORY ACUTE…
globenewswire.com AB Science announces new publication on Medrxiv highlighting clinical benefit with masitinib in Amyotrophic Lateral Sclerosis patients prior any complete loss of function PRESS RELEASE AB SCIENCE ANNOUNCES NEW PUBLICATION ON MEDRXIV HIGHLIGHTING CLINICAL BENEFIT WITH MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS PATIENTS PRIOR ANY COMPLETE LOSS OF FUNCTION Significant…
globenewswire.com AB Science announces the successful completion of a EUR 2.8 million private placement PRESS RELEASE AB SCIENCE ANNOUNCES THE SUCCESSFUL COMPLETION OF A EUR 2.8 MILLION PRIVATE PLACEMENT AB SCIENCE IS FULLY FINANCED TO FINISH PHASE 1 OF AB8939 IN AML AND TO EXECUTE AN EXPANSION PHASE…